On June 9, 1999, FDA issued a public health advisory to physicians concerning the risks of liver toxicity associated with the use of Trovan (trovafloxacin, an oral antibiotic) and Trovan-IV (alatrofloxacin, the intranvenous formulation of the drug). Trovan is an antibiotic used to treat many different types of infections. Trovafloxacin was approved for marketing in December, 1997, and became available on the market in February, 1998. Based on new safety data related to serious liver injury, FDA is advising physicians that trovafloxacin should be reserved for use only in patients who meet the specific criteria outlined in the following public health advisory.
Do Not Buy Trovan Over the Internet
To learn more about buying drugs safely, please see